Despite widespread implementation of the 21-gene test, some minorities and Medicaid patients have less access to testing. We also identified patients for whom the appropriateness of testing was questionable due to comorbid medical conditions or advanced age. Our data illustrate the need to improve coding to ensure that reimbursement of genomic tests is tied to appropriate use and to discourage overutilization.
